FASPX
Price
$52.67
Change
-$0.27 (-0.51%)
Updated
Sep 20 closing price
VMVAX
Price
$86.17
Change
-$0.37 (-0.43%)
Updated
Sep 20 closing price
Ad is loading...

FASPX vs VMVAX

Header iconFASPX vs VMVAX Comparison
Open Charts FASPX vs VMVAXBanner chart's image
Fidelity Advisor Value Strategies M
Price$52.67
Change-$0.27 (-0.51%)
VolumeN/A
CapitalizationN/A
Vanguard Mid-Cap Value Index Admiral
Price$86.17
Change-$0.37 (-0.43%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
FASPX vs VMVAX Comparison Chart
Loading...
VS
FASPX vs. VMVAX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FASPX is a Buy and VMVAX is a StrongBuy.

FUNDAMENTALS
Fundamentals
VMVAX has more cash in the bank: 30.5B vs. FASPX (2.29B). VMVAX pays higher dividends than FASPX: VMVAX (2.14) vs FASPX (0.24). FASPX was incepted earlier than VMVAX: FASPX (38 years) vs VMVAX (13 years). FASPX is a more actively managed with annual turnover of: 59.00 vs. VMVAX (22.00). FASPX has a lower initial minimum investment than VMVAX: FASPX (0) vs VMVAX (3000). VMVAX annual gain was more profitable for investors over the last year : 25.35 vs. FASPX (19.45). FASPX return over 5 years is better than : 60.66 vs. VMVAX (48.82).
FASPXVMVAXFASPX / VMVAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence38 years13 years-
Gain YTD9.59214.94664%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets2.29B30.5B8%
Annual Yield % from dividends0.242.1411%
Returns for 1 year19.4525.3577%
Returns for 3 years20.1020.7197%
Returns for 5 years60.6648.82124%
Returns for 10 years33.23100.8833%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AUUD0.790.01
+0.67%
Auddia
CTLT60.00-0.11
-0.18%
CATALENT
JAMF18.49-0.09
-0.48%
Jamf Holding Corp
ARCT20.61-0.41
-1.95%
Arcturus Therapeutics Holdings
ANVS8.47-0.17
-1.97%
Annovis Bio